伤口世界
  • 首页
  • 病情图文
    • 糖尿病足
    • 压疮
    • 感染伤口
    • 造口
    • 溃疡
      • 动脉性溃疡
      • 静脉性溃疡
      • 放射性溃疡
    • 烧伤
    • 创伤
    • 少见伤口
    • 祛疤止痒
    • 皮肤病
  • 医师讲座
  • 名医介绍
    专业服务
    • 糖尿病足
    • 压疮
    • 造口
    • 溃疡
    • 烧伤
    蔡道章院长

    Custom Mod Mega1

    主任医师、教授、博导,南方医科大学第三附属医院(广东省骨科医院)院长

    • 中德骨科伤口管理学校校长
    • 广东省骨科研究院运动医学研究所所长
    • 广东省内运动医学专业唯一的博士研究生导师
    • 美国哈弗大学医学院骨科访问学者
    • 专业特长处于省内领先、国内或国际先进水平以上
    • 2018年获得“国之名医卓越建树”荣誉称号
    • 2017年被评为全国卫生计生系统先进工作者、广东省医学领军人才
    • 中国医师协会运动医师分会副会长
    • STCOT中国部运动医学分会副主任委员
    • 广东省医学会关节外科分会主任委员
    • 广东省医学会运动医学会分会名誉主任委员
    • 独立承担过国家“863”课题,主持过10余项省、部级科研项目
    • 多份专业杂志编委
  • 文献精选
    伤口分类
    • 糖尿病足
    • 压疮
    • 感染伤口
    • 造口
    • 溃疡
    • 烧伤
    • 更多关于伤口信息
    最新文献
    • Phenylketonuria and type 1 diabetes: a clinical and nutritional challenge in a young adult—a case report 2026-06-21 00:00

      Carmine Piccolo1  · Sara de Candia1  · Annalisa Natalicchio1  · Sergio Di Molfetta1  · Irene Caruso1  · Luigi Laviola1  · Francesco Giorgino1  · Gian Pio Sorice

      Received: 16 December 2025 / Accepted: 11 March 2026 © The Author(s) 2026

      Abstract

      Aims Phenylketonuria and type 1 diabetes are lifelong metabolic disorders requiring complex and potentially conflicting nutritional strategies. Their coexistence is rare, yet management may become particularly challenging during transition from pediatric to adult care. We describe the case of a young adult with phenylketonuria who developed type 1 diabetes.

      Methods A 27-year-old man with longstanding phenylketonuria was referred to an adult metabolic-diabetes center after the diagnosis of type 1 diabetes. Clinical, biochemical, nutritional, and continuous glucose monitoring data were reviewed. The intervention included structured therapeutic education, transition from fixed insulin doses to a dynamic regimen based on carbohydrate counting, and revision of medical nutrition therapy using phenylketonuria-adapted low-protein foods and sugar-free phenylalanine-free amino acid supplements.

      Results At diagnosis, HbA1c was 11.5%, with markedly reduced C-peptide levels and high titer anti-GAD antibodies. Ini-tial diabetes management was associated with poor adherence to the phenylketonuria diet, increased intake of conventional protein sources, and elevated phenylalanine levels. After individualized insulin titration and nutritional intervention, HbA1c improved from 11.5% to 7.8%, phenylalanine levels decreased from 842 to 705 μmol/L, insulin requirement declined from 0.55 to 0.3 IU/kg/day, and continuous glucose monitoring showed improved glycemic control without increased hypoglyce-mia. The Glycemia Risk Index improved from high-risk Zone E to low-intermediate-risk Zone B.

      Conclusions This case highlights the need for personalized multidisciplinary care integrating continuous glucose monitor-ing, carbohydrate counting, and phenylketonuria specific nutrition to optimize both metabolic conditions.

      Keywords Phenylketonuria · Type 1 diabetes · CGM · multidisciplinary approach

    • Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systems 2026-06-18 00:00

      Nicolò Diego Borella1  · Antonio Ferramosca2  · Giona Castagna1  · Silvia Ippolito1  · Sara Ceresoli2  · Antonio Taverna1  · Beatrice Sonzogni2  · Roberto Trevisan1,3 · Giuseppe Lepore1

      Received: 6 March 2024 / Accepted: 15 October 2024 / Published online: 22 November 2024 © The Author(s) 2024

      Abstract

      Context Advanced hybrid closed loop (AHCL) systems currently represent the most advanced modality of insulin therapy.

      Aim To compare the night-time (from 00 to 07 a.m.) effectiveness in achieving recommended glycemic targets of three dif-ferent AHCL systems in adults with type 1 diabetes (T1D).

      Methods We retrospectively evaluated 55 adults with T1D (mean age 41±16 years, male 40%, diabetes duration 19.4±11.4 years, BMI 24.1±4.1 kg/m2 ) with similar glycemic control (GMI 7.0–7.4%). Twenty-two participants were using the Minimed 780G system, 18 the Tandem t:slim X2 with Control-IQ system and 15 the DBLG1 system. Continuous glucose monitoring derived metrics and insulin requirement of 14 consecutive nights were

      Results All three groups achieved the recommended mean TIR>70%, mean TBR<4%, and mean CV<36% with a similar insulin requirement (Minimed 780G system: TIR 73.9±11.2%, TBR 0.9±1.2%, CV 29±6.7%; Tandem t:slim X2 with Con-trol-IQ system: TIR 74.1±11.1%, TBR 1.1±1.0%, CV 34.5±6.6%; DBLG1 System TIR 71.7±11.3%, TBR 1.4±3.7%, CV 32.4±7.1%). Tight TIR% (70–140 mg/dl) was significantly higher (p<0.01) in the Tandem t:slim X2 with Control-IQ group (51.5±9.8%) when compared to Minimed 780G group (42.1±13.7%) and DBLG1 System (40.1±10.5%). In all three groups the insulin infusion similarly decreased from midnight to 05.00 am and then increased.

      Conclusions All the three AHCL systems achieved the recommended TIR, TBR and CV without difference in insulin requirement. The Tandem Control-IQ system obtained a higher tight TIR.

  • 互动快递
  • 首页
  • 病情图文
    • 糖尿病足
    • 压疮
    • 感染伤口
    • 造口
    • 溃疡
      • 动脉性溃疡
      • 静脉性溃疡
      • 放射性溃疡
    • 烧伤
    • 创伤
    • 少见伤口
    • 祛疤止痒
    • 皮肤病
  • 医师讲座
  • 名医介绍
    • 专业服务
      • 糖尿病足
      • 压疮
      • 造口
      • 溃疡
      • 烧伤
    • 蔡道章院长
  • 文献精选
    • 伤口分类
      • 糖尿病足
      • 压疮
      • 感染伤口
      • 造口
      • 溃疡
      • 烧伤
      • 更多关于伤口信息
    • 最新文献
  • 互动快递
  • 当前位置: 
  • 首页
  • 文献精选

文献精选

含活细胞冻存胎盘膜治疗慢性伤口的前瞻性、单中心、开放性临床病例序列研究

含活细胞冻存胎盘膜治疗慢性伤口的前瞻性、单中心、开放性临床病例序列研究

伤口世界,
2019-09-16 00:00
发布于 文献精选
1774 Views
0 Comment
猪皮细胞外基质联合负压吸引治疗促进4期压疮愈合

猪皮细胞外基质联合负压吸引治疗促进4期压疮愈合

伤口世界,
2019-09-16 00:00
发布于 文献精选
2016 Views
0 Comment
农村地区糖尿病足溃疡病原菌分布及药敏分析

农村地区糖尿病足溃疡病原菌分布及药敏分析

伤口世界,
2019-09-16 00:00
发布于 文献精选
1696 Views
0 Comment
菲律宾传统中药膏剂治疗下肢静脉溃疡

菲律宾传统中药膏剂治疗下肢静脉溃疡

伤口世界,
2019-09-16 00:00
发布于 文献精选
1839 Views
0 Comment
  • 首页
  • 440
  • 441
  • 442
  • 443
  • 444
  • 445
  • 446
  • 447
  • 448
  • 449
  • 末页
第445页 共483页

Categories

  • 病情图文
  • 文献精选
  • 名医介绍
  • K2 Content
  • Phenylketonuria and type 1 diabetes: a clinical and nutritional challenge in a young adult—a case report 2026-06-21 00:00

    Carmine Piccolo1  · Sara de Candia1  · Annalisa Natalicchio1  · Sergio Di Molfetta1  · Irene Caruso1  · Luigi Laviola1  · Francesco Giorgino1  · Gian Pio Sorice

    Received: 16 December 2025 / Accepted: 11 March 2026 © The Author(s) 2026

    Abstract

    Aims Phenylketonuria and type 1 diabetes are lifelong metabolic disorders requiring complex and potentially conflicting nutritional strategies. Their coexistence is rare, yet management may become particularly challenging during transition from pediatric to adult care. We describe the case of a young adult with phenylketonuria who developed type 1 diabetes.

    Methods A 27-year-old man with longstanding phenylketonuria was referred to an adult metabolic-diabetes center after the diagnosis of type 1 diabetes. Clinical, biochemical, nutritional, and continuous glucose monitoring data were reviewed. The intervention included structured therapeutic education, transition from fixed insulin doses to a dynamic regimen based on carbohydrate counting, and revision of medical nutrition therapy using phenylketonuria-adapted low-protein foods and sugar-free phenylalanine-free amino acid supplements.

    Results At diagnosis, HbA1c was 11.5%, with markedly reduced C-peptide levels and high titer anti-GAD antibodies. Ini-tial diabetes management was associated with poor adherence to the phenylketonuria diet, increased intake of conventional protein sources, and elevated phenylalanine levels. After individualized insulin titration and nutritional intervention, HbA1c improved from 11.5% to 7.8%, phenylalanine levels decreased from 842 to 705 μmol/L, insulin requirement declined from 0.55 to 0.3 IU/kg/day, and continuous glucose monitoring showed improved glycemic control without increased hypoglyce-mia. The Glycemia Risk Index improved from high-risk Zone E to low-intermediate-risk Zone B.

    Conclusions This case highlights the need for personalized multidisciplinary care integrating continuous glucose monitor-ing, carbohydrate counting, and phenylketonuria specific nutrition to optimize both metabolic conditions.

    Keywords Phenylketonuria · Type 1 diabetes · CGM · multidisciplinary approach

  • Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systems 2026-06-18 00:00

    Nicolò Diego Borella1  · Antonio Ferramosca2  · Giona Castagna1  · Silvia Ippolito1  · Sara Ceresoli2  · Antonio Taverna1  · Beatrice Sonzogni2  · Roberto Trevisan1,3 · Giuseppe Lepore1

    Received: 6 March 2024 / Accepted: 15 October 2024 / Published online: 22 November 2024 © The Author(s) 2024

    Abstract

    Context Advanced hybrid closed loop (AHCL) systems currently represent the most advanced modality of insulin therapy.

    Aim To compare the night-time (from 00 to 07 a.m.) effectiveness in achieving recommended glycemic targets of three dif-ferent AHCL systems in adults with type 1 diabetes (T1D).

    Methods We retrospectively evaluated 55 adults with T1D (mean age 41±16 years, male 40%, diabetes duration 19.4±11.4 years, BMI 24.1±4.1 kg/m2 ) with similar glycemic control (GMI 7.0–7.4%). Twenty-two participants were using the Minimed 780G system, 18 the Tandem t:slim X2 with Control-IQ system and 15 the DBLG1 system. Continuous glucose monitoring derived metrics and insulin requirement of 14 consecutive nights were

    Results All three groups achieved the recommended mean TIR>70%, mean TBR<4%, and mean CV<36% with a similar insulin requirement (Minimed 780G system: TIR 73.9±11.2%, TBR 0.9±1.2%, CV 29±6.7%; Tandem t:slim X2 with Con-trol-IQ system: TIR 74.1±11.1%, TBR 1.1±1.0%, CV 34.5±6.6%; DBLG1 System TIR 71.7±11.3%, TBR 1.4±3.7%, CV 32.4±7.1%). Tight TIR% (70–140 mg/dl) was significantly higher (p<0.01) in the Tandem t:slim X2 with Control-IQ group (51.5±9.8%) when compared to Minimed 780G group (42.1±13.7%) and DBLG1 System (40.1±10.5%). In all three groups the insulin infusion similarly decreased from midnight to 05.00 am and then increased.

    Conclusions All the three AHCL systems achieved the recommended TIR, TBR and CV without difference in insulin requirement. The Tandem Control-IQ system obtained a higher tight TIR.

  • The potential of precision diabetology for type 2 diabetes treatment— evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials 2026-06-17 00:00

    Oliver Kuss1,2,3  · Michael Roden3,4,5  · Sabrina Schlesinger1,3  · Annika Hoyer6

    Received: 27 May 2024 / Accepted: 23 November 2024 / Published online: 12 December 2024 © The Author(s) 2024

    Abstract

    Aims Two prerequisites must be met for the precision treatment approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in case of treatment heterogeneity, clinical predictors to identify people who would benefit from one treatment more than from others must be available. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. We recently applied this approach to the treatment of type 2 diabetes for the clinical outcomes of glycaemic control and body weight and repeat it for the clinical outcome of all-cause mortality.

    Methods We performed a meta-regression analysis using digitalized individual participant information on time to death from 10 large cardiovascular outcome trials (7563 deaths from 99,746 participants) on DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors with respect to the variability of all-cause mortality and its potential predictors after treatment.

    Results The adjusted difference in log(SD) values of time to death between the verum and placebo arms was −0.036 (95%- CI: −0.059; −0.013), showing larger variability of time to death in the placebo arms. No clinical predictors were found to explain treatment heterogeneity.

    Conclusions This analysis suggests that the potential of the precision treatment approach in type 2 diabetes is low, at least with regard to improvement of all-cause mortality in population with high cardiovascular risk. This extends our previous findings for the clinical outcomes of glycaemic control and body weight.

    Keywords Dipeptidyl peptidase-4 inhibitors · Glucagon-like peptide 1 · HbA1c · Meta-regression · Precision medicine · Sodium–glucose transporter 2 inhibitors · Type 2 diabetes mellitus

Popular Tags

  • 糖尿病足
  • 烧伤
  • 创伤
  • 祛疤止痒
  • 皮肤病
  • 造口
  • 溃疡
  • 动脉性溃疡
  • 静脉性溃疡
  • 放射性溃疡

伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。

 

消息订阅

关注伤口世界动态,了解专业领域最新科技
Copyright © 2026 中诺医疗. All Rights Reserved
皖ICP备19014494号-1

学术会议

2019广东省医疗行业协会伤口管理分会年会

扫一扫了解详情:

 

  • 2019年6月15日 中国广州
  • 主办单位:广东省医疗行业协会伤口管理分会

伤口世界提示

任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。

网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。